A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Inclusion Criteria:

* Symptomatic multiple myeloma requiring treatment
* Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapy
* At least 18 years of age
* Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 × 10\^6 CD34+ cells/kg based on patient body weight.
* Adequate organ function as measured by:

  * Cardiac function: Left ventricular ejection fraction at rest ≥40%
  * Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine amino transferase (AST/ALT) ≤3 × ULN
  * Renal function: Creatinine clearance ≥40 mL/minute (measured or calculated/estimated)
  * Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for hemoglobin \[Hgb\]), forced expiratory volume in 1 second (FEV1), forced expiratory vital capacity (FVC) ≥50% of predicted value
  * Oxygen saturation ≥92% on room air
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
* Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria:

* Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to ASCT
* Prior stem cell transplant (autologous or allogeneic)
* Smoldering MM not requiring therapy
* Plasma cell leukemia
* Systemic amyloid light chain amyloidosis
* Active bacterial, viral, or fungal infection
* Seropositive for human immunodeficiency virus (HIV)
* Known, active hepatitis A, B, or C Infection
* Pregnant or breastfeeding.
* Receiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on Day +100.
* Hypersensitive or intolerant to any component of the study drug(s) formulation
* Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor, etc) or undergoing apheresis \< 14 days prior to the start of treatment on protocol (Day -7).